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Abstract
Therapeutic apheresis is an extracorporeal treatment that selectively separates abnormal cells or substances from the blood that are linked with 
or cause certain disease states. It is widely used in transplantation medicine as an adjunctive therapeutic option.
In kidney transplantation (KT), recurrent and de novo glomerular diseases represent the third most common cause of graft failure beyond 
the first year after transplantation, as current therapeutic options are limited. Evidence to support the use of therapeutic apheresis in these 
conditions is scarce, as it is only supported by observational studies. The purpose of this review was to examine and clarify the potential role of 
therapeutic apheresis and describe current evidence in the treatment of recurrent and de novo glomerular diseases after KT.
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Introduction
Recurrent and de novo glomerular diseases after kidney 
trans plantation (KT) have a powerful impact on transplant 
sur vival. After death with a functioning graft and chronic 
rejection represent the third most common cause of graft fail-
ure beyond the first year from KT (1). The Renal Allograft 
Disease Registry (RADR) data, a consortium of six Amer-
ican transplant centers, examining the rate of recurrent and 
de novo glomerular diseases after KT, showed a prevalence 
of 2.8% after 2 years, 9.8% after 5 years, and 18.5% after 
8 years of follow-up. In addition, the occurrence of graft fail-
ure in recipients with recurrent or de novo glomerular dis-
ease was double that of those who did not experience these 
clinical conditions after KT (2). Briganti et al., in analyzing 
registry data from the Australia and New Zealand Dialy-
sis and Transplant Registry (ANZDATA), found that 0.5% 
of grafts within 1 year after KT, 3.7% within 5 years, and 
8.4% within 10 years were lost due to recurrent glomerular 
disease (1). However, the incidence and outcomes of recur-
rence vary to a great extent. For example, primary focal seg-
mental glomerulosclerosis (FSGS) and C3 glomerulopathy 
recur frequently; however, the disease tends to have a slow 
progression in terms of graft loss, and graft survival beyond 
10 years is typical (1). On the other hand, anti-glomerular 
basement membrane (GBM) disease and anti-neutrophil 
cytoplasmic antibody (ANCA)- associated vasculitis recur 
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coming from patients with recurrent FSGS after KT result in 
a substantial increase in albuminuria.
In a systematic review of the literature, Ponticelli high-
lighted that about 70% of children and 63% of adult trans-
plant recipients with FSGS recurrence who have been treated 
with TPE or IA sessions had complete or partial remission 
of proteinuria (12). Two recent meta-analyses have published 
comparable outcomes (13,14).
There are currently no precise indications on the duration 
and frequency of TPE sessions. A therapeutic regimen of 
TPE sessions typically used consists of 1.5 plasma volume 
exchanges for three consecutive days following treatment on 
alternate days for a total duration of 2 weeks (15).
TPE sessions have also been applied in protocols with var-
ious immunosuppressive agents. In a series of 10 patients, 
Canaud et al. (16) showed favorable outcomes by combining 
frequent TPE sessions, slowly tapered down for 9 months, 
with intravenous cyclosporine plus high-dose steroids and 
mycophenolate.
The use of Rituximab (RTX) in the recurrence of FSGS 
after KT has rapidly increased with beneficial outcomes in 
the last 10 years (17,18). RTX, other than being a selective 
depleting agent of B lymphocytes, provides a direct protec-
tive effect on podocytes. Fornoni et al. showed that RTX 
protects sphingomyelin phosphodiesterase acid-like 3b 
(SMPDL-3b) and acid sphingomyelinase (ASMase) by bind-
ing to  SMPDL-3b, a protein that is mainly expressed in the 
lipid rafts of podocytes, and could be a target of the permea-
bility factor (19,20). As evidenced in several case reports, the 
use of RTX combined with TPE looks to be more effective 
than the sole use of TPE (21,22). Of importance, the mean 
percentage of RTX removal during a first TPE session range 
between 47 and 54% when TPE is performed between 24 and 
72 h after RTX infusion (23). This pharmacokinetic obser-
vation should be taken into account for RTX re-dosing after 
TPE sessions.
Recently, Martin-Moreno et al. (24) presented the case 
of a male patient with severe recurrence of FSGS (massive 
proteinuria) after KT without response to TPE sessions, and 
partial remission to a combination of IA and cycles of RTX. 
The importance of IA, as an alternative to TPE, in the treat-
ment of recurrent FSGS after KT, and in general in the case 
of idiopathic nephrotic syndrome, has been highlighted in a 
recent review by Kronbichler et al. (25). Now randomized 
trials are needed to draw conclusions on whether IA is supe-
rior to TPE in terms of efficacy, safety, and quality of life.
Complement-mediated atypical hemolytic  
uremic syndrome
Complement-mediated aHUS is a rare disease that mainly 
occurs due to gene mutations of complement factors. There 
have been identified loss-of-function mutations in regulatory 
only rarely, but when it does, it is likely to cause rapid graft 
loss. In the case of complement- mediated atypical hemolytic 
uremic syndrome (aHUS), recurrence and its impact on graft 
survival are dependent on the complement pathway muta-
tion responsible.
The treatment of these conditions is often challenging for 
transplant nephrologists. Therapeutic apheresis (TA) tech-
niques are widely used in KT in desensitization protocols for 
ABO-incompatible KT, in patients with preformed HLA- 
antibodies and those undergoing treatment for antibody- 
mediated rejection (AMR). Although evidence from 
adequately powered randomized controlled trials support-
ing the use of TA to treat recurrent and de novo glomerular 
diseases after KT is lacking, because of the rarity of these 
diseases, the use of TA, mainly therapeutic plasma exchange 
(TPE), is widespread in transplant centers. This review exam-
ines the evidence supporting the application of TA in treat-
ing recurrent and de novo glomerular diseases after KT.
Recurrence of primary focal segmental 
glomerulosclerosis
Around 30% of the patients with primary FSGS experience 
disease recurrence after first KT, and in one series, early graft 
loss occurred at an average of 24 months after diagnosis of 
recurrence in 14 among 25 patients with recurrent FSGS (3). 
The possibility of the disease to recur is even higher than 
75% after a second KT when the first graft failed because of 
recurrence (4).
Primary FSGS is probably triggered by a circulating 
permeability factor that targets the glomerular filtration 
barrier, especially podocytes. Until now, different plasma 
molecules have been hypothesized to be implicated in the 
disease pathogenesis. However, none of  them have demon-
strated a clear pathogenic correlation (5). Delville et al. (6) 
have recently described a panel of  seven antibodies (CD40, 
PTPRO, CGB5, FAS, P2RY11, SNRPB2, and APOL2) 
that predict FSGS recurrence after KT, with 92% accuracy. 
An elevation of  the titers of  anti-CD40 antibody alone, in 
the period before transplantation, had the best prediction 
(78% accuracy), with the disease recurrence after KT (6). 
Furthermore, the administration of  anti-CD40 antibodies, 
purified from patients with FSGS recurrence, in cultures 
of  human podocytes has been proven to be particularly 
 pathogenic (6).
Over the years, for removing the putative circulating perme-
ability factor responsible for the pathogenesis of the disease, 
TPE and Immuno-Absorption (IA) (with either a staphy-
lococcal protein A [SPA] or anti-IgG column), alone or in 
sequence with cyclophosphamide, have been employed with 
benefit in patients with recurrent disease after KT (7–11). In 
support of this hypothesis, Dantal et al. (11) showed that the 
administration to rats of material eluted from SPA columns 
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When TMA is associated with AMR, the combined use of 
TPE and intravenous immunoglobulin (IVIG) confer favor-
able outcomes for the survival of the graft (38). Eculizumab 
becomes the preferred treatment in AMR-associated TMA 
if  hemolysis persists in spite of the use of TPE, and in the 
TPE-dependent patients (34).
Recurrence of C3 glomerulopathies
C3 glomerulopathies (C3G) are rare forms of glomerulo-
nephritis that include dense deposit disease (DDD) and 
C3  glomerulonephritis (C3GN), distinguished by structural 
characteristics observed on electron microscopy (39). Both 
subtypes are caused by excessive activation of the alter-
native complement pathway, which results either from C3 
convertase- stabilizing autoantibodies, called C3 nephritic fac-
tors (C3NeFs), and other antibodies directed against factor 
B and factor H or from mutations of factor I, MCP, C3, fac-
tor B, factor H, and mutations of the complement factor H 
related proteins (CFHRs) gene cluster (40).
The recurrence rate of DDD after KT is approximately 
80–100%, while the reported recurrence rate of C3GN 
is greater than 50% (41,42). Factors associated with an 
increased risk of recurrence include persistently low C3 lev-
els and living-donor KT (43). Recurrent C3G is typically 
manifested within 1–2 years following KT and often results 
in graft loss (50% of patients) (41,42). Recurrence occurs 
earlier and is more aggressive if  associated with monoclonal 
 gammopathy (42).
Currently, there are no controlled studies on which to base 
therapeutic recommendations for recurrent C3G. We suggest 
that patients should be switched to mycophenolate mofetil 
(MMF) therapy, if  it is not already part of their maintenance 
immunosuppression regimen.
TPE represents a therapy of unclear benefit. TPE has been 
proved to prevent disease progression in some patients with 
DDD in native kidneys with circulating C3NeFs, probably 
by removal of the pathologic autoantibodies (44). How-
ever, McCaughan et al. (45) reported that TPE was inef-
fective in a patient with recurrent DDD after KT, in spite 
of effective removal of C3NeF. Recently, Kumar et al. (46) 
demonstrated response to TPE in three of four patients with 
early recurrent C3G (median time for posttransplant recur-
rence was 3 days) and circulating autoantibodies to com-
plement pathway regulators (two cases had positive C3NeF 
and one had anti-complement factor-H autoantibodies). All 
patients underwent five sessions of alternate-day TPE (40 ml/
kg/ session with membrane filter) using fresh-frozen plasma 
(FFP) and albumin as the replacement fluid (46). If  TPE is 
used in such patients, we suggest alternate-day TPE, at least 
initially. Then, TPE should be maintained until C3NeF levels 
decrease by at least 50%, provided that there is simultaneous 
stabilization of graft function.
proteins of the alternative pathway of the complement system 
(factor H, factor I, and membrane cofactor protein [MCP]) 
or gain-of-function mutations in activators (C3 and factor B) 
(26). Furthermore, complement-mediated aHUS may be the 
result of autoimmune processes, through the production of 
auto-antibodies against complement regulatory proteins (26).
Mutations affecting the protein factors H, I, B, and C3 are 
associated with a high risk of recurrence (75%), and an even 
higher risk of graft failure in the first posttransplant year 
(over 90%), as these are circulating proteins that persist in 
recipients (27). In contrast, mutations that affect MCP are 
associated with a low degree of recurrence (approximately 
20%) and better survival of the graft since the transplanted 
kidney expresses the normal protein (28).
TPE is capable of removing auto-antibodies against 
complement proteins and mutant circulating comple-
ment regulatory proteins, replacing them with no defective 
components; but, its use in the prevention of recurrence, 
before  transplantation, and in the case of recurrence of 
complement- mediated aHUS posttransplantation has shown 
poor therapeutic results (29).
The introduction of eculizumab, an anti-C5 monoclonal 
antibody, positively changed the outcomes and questioned 
the role of TPE in the treatment of aHUS. The alleged 
clinical benefits of TPE in prophylactic protocols before 
transplantation, in addition to eculizumab used by some 
transplant centers (30), remain unclear and controversial. 
TPE remains a therapeutic alternative if  eculizumab is not 
available for patients with autoantibodies against factor H 
and in the case of persistent thrombocytopenia after the ini-
tial days of administration of eculizumab (31,32). Attention 
should be made in case of a TPE session after eculizumab 
infusion because of increased drug clearance TPE induced. 
Therefore, an extra dose of eculizumab within 60 min after a 
TPE is recommended (33).
De novo thrombotic microangiopathy
The occurrence of de novo thrombotic microangiopathy 
(TMA) posttransplantation could be the result of pathoge-
netic processes that induce TMA in the general population. 
However, the most common causes that induce TMA after 
KT are: i) drug-induced TMA due to calcineurin inhibi-
tors and mammalian target of rapamycin (mTOR) inhibi-
tors, ii) ischemia-reperfusion injury, iii) AMR, and iv) viral 
 infections (34).
If  clinical improvement does not occur after changing the 
immunosuppressive regimen, in the case of drug-induced 
TMA, or after treating the underlying infection, TPE may 
find application in an attempt to stop further damage to the 
graft even if  the levels of evidence are low for such use (35). 
If  eculizumab is available, it becomes the treatment of choice 
in these cases (36,37).
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Among patients who have a known serum factor defi-
ciency, as an example, a genetic cause of factor H deficiency, 
we suggest to begin intermittent FFP infusions or TPE 
before KT and extend this treatment after transplantation 
while monitoring for clinical evidence of disease recurrence. 
If  such patients remain free of recurrence, the FFP infusions 
or TPE may be tapered off  with continued monitoring for 
signs of recurrence.
Eculizumab is an alternative to TPE, which has been used 
with variable success in patients with recurrent C3G (47,48). 
Avacopan, an orally administered selective C5a receptor 
inhibitor, which was recently found to be effective in the 
treatment of ANCA-associated vasculitis (49), is now tested 
in a randomized, double-blind, placebo-controlled, phase 
2 study (ClinicalTrials.gov Identifier: NCT03301467), in 
biopsy- proven C3G, either DDD or C3GN, with or without 
a renal transplant.
Antiphospholipid antibody syndrome and  
lupus nephritis
Antiphospholipid antibody syndrome is a multisystem auto-
immune disease clinically manifested by multiple thrombotic 
episodes in both venous and arterial circulation, and sero-
logically characterized by the presence of antiphospholipid 
(aPL) antibodies. APS can represent a primary nosological 
entity or be secondary to other autoimmune diseases, mainly 
systemic lupus erythematosus (SLE) (50).
The kidney can be damaged by the occlusion of the 
glomerular capillaries up to that of the main artery and 
vein (50). Graft loss due to a thrombotic event of graft vein, 
graft artery, or even a TMA in the early postoperative period 
represents the most frequent causes of KT failure in patients 
with Antiphospholipid syndrome (APS) (51). In addition, 
several studies have highlighted the fact that hemodialysis 
patients, and consequently the recipients of KT, have a high 
prevalence of circulating aPL, potentially harmful to the 
graft (52,53).
Treatment of KT recipients affected by APS with long-term 
warfarin, for the prevention of thrombotic events, is strongly 
recommended. In addition, many transplant centers prefer to 
treat, in the peritransplant period, all patients with aPL posi-
tivity and history of thrombotic events (54,55). However, the 
treatment of these patients with oral anticoagulants increases 
the risk of bleeding, which could result in an early loss of 
graft in the immediate posttransplant period. Furthermore, it 
must be considered that thrombotic events can occur in 40% 
of cases even during anticoagulant therapy (56).
Prophylactic treatment with TPE for the removal of cir-
culating APL, in addition to maximal oral anticoagulant 
therapy, before a living-donor KT has proven effective in a 
patient with primary APS (57) and in the case of a recipi-
ent with secondary APS due to SLE (58). However, in cases 
of catastrophic APS (CAPS), which occur with diffuse 
TMA (vascular occlusion affecting three or more organ sys-
tems)  (59), prophylactic treatment with eculizumab to pre-
vent recurrence after KT must be considered as the most 
suitable treatment after being successfully used in a KT 
recipient together with systemic anticoagulation and stan-
dard immunosuppression (60).
Barbour et al. (51) reported a case of acute recurrence of 
TMA in a recipient of KT affected by APS and lupus nephri-
tis, which has been effectively treated with TPE even with the 
presence of moderate irreversible damage to the functional-
ity of the graft. These data suggest that further studies are 
required.
Recurrent and de novo anti-glomerular  
basement membrane antibody disease
Anti-GBM antibody disease histologically recurs to the 
graft in up to 50% of cases if  circulating anti-GBM antibod-
ies persist at the time of transplantation (61,62). However, 
clinically manifested cases of recurrent anti-GBM antibody 
disease are limited, as most patients are asymptomatic (61). 
Different cohorts described that de novo anti-GBM antibody 
disease can occur in 0.5–10% of KT recipients with Alport 
syndrome, developing anti-GBM antibodies to a collagen 
component expressed by the graft [alpha5 (IV) NC1] that is 
missing in patients with Alport (63–65). The explanation for 
the differences in the incidence may relate to different trans-
plant immunosuppression protocols or different thresholds 
for diagnosis and coding of posttransplant anti-GBM anti-
body disease used in the various series.
The therapeutic approach is the same as that used in non-
transplanted patients. TA must be used promptly for the 
removal of the harmful autoantibodies, in addition to cor-
ticosteroids plus cyclophosphamide or RTX, which are use-
ful to inhibit further antibody production (62). AI and TPE 
have similar results (66,67).
The endopeptidase IdeS (Immunoglobulin G degrad-
ing enzyme of Streptococcus pyogenes), an enzyme that is 
capable of cleaving both circulating and membrane-bound 
human IgG subclasses into F(ab’)2 and Fc fragments, is a 
promising new therapeutic approach in the treatment of 
anti-GBM antibody disease. Soveri et al. (68) showed rapid 
clearance of anti-GBM antibodies (within minutes) in three 
no transplant patients with severe, and refractory to stan-
dard treatment, anti-GBM nephritis. Rebound of anti-GBM 
antibodies occurred in all three cases, even if  it was mild in 
patients 1 and 3, and easily managed with TPE. Clinical tri-
als are necessary to determine the clinical utility of this new 
treatment option. GOOD-IDES is an open-label ongoing 
phase II study to evaluate the efficacy and safety of IdeS in 
anti-GBM antibody disease (ClinicalTrials.gov identifier: 
NCT03157037).
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collaboration is demanded to improve the quality of future 
studies in this area.
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